This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Imaging in patients presenting with the symptoms of acute ischemic stroke has two objectives: assessment of the immediate pathophysiologic state of the cerebral circulation and tissue and assessment of the underlying disease. Diagnosis of the underlying disease will help in the choice of adequate secondary prophylaxis. Assessment of the brain's current pathophysiologic state is a prerequisite to choosing adequate treatment and is the more urgent of the two objectives. The imaging tool has to be available and employed quickly within the first hours after stroke onset. The imaging modality should reliably differentiate cerebral ischemia from other causes of a sudden central neural deficit. In addition, it should be able at an early stage to differentiate normal brain tissue from tissue at risk and from tissue that is already dying.
Historically, vascular imaging was developed first and provided the rationale for surgery in cases of high-grade carotid stenoses and for prophylaxis with antiplatelet agents. Brain tissue imaging with CT was developed later and this technique allowed the diagnosis of ischemic stroke and thus thrombolytic treatment, which recently has been shown to be beneficial.1,2 A variety of new tools are now available for vascular and tissue imaging: ultrasound, CT angiography (CTA), MRI and MR spectroscopy (MRS), single photon emission tomography, and positron emission tomography.
Computed tomography and MRI/MRS are most promising for meeting the above-mentioned objectives in the clinical setting of acute stroke. Magnetic resonance perfusion imaging directly shows ischemic areas and magnetic resonance diffusion imaging immediately shows its sequelae with high sensitivity. However, the prospective value of MRI for treatment is not yet determined. Although CT is considered relatively insensitive in acute ischemic stroke by some authors, all major clinical trials are using CT before the randomization of patients. This is explained by the wide availability and high practicability of …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease
Dr. Rizwan S. Akhtar and Dr. Sarah Brooker